- Home
- GECC vs GLSI Comparison
GECC vs GLSI Comparison
Compare GECC & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GECC
- GLSI
- Stock Information
- Founded
- GECC 2016
- GLSI 2006
- Country
- GECC United States
- GLSI United States
- Employees
- GECC N/A
- GLSI N/A
- Industry
- GECC Finance: Consumer Services
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- GECC Finance
- GLSI Health Care
- Exchange
- GECC Nasdaq
- GLSI Nasdaq
- Market Cap
- GECC 122.4M
- GLSI 133.4M
- IPO Year
- GECC N/A
- GLSI 2020
- Fundamental
- Price
- GECC $10.58
- GLSI $9.64
- Analyst Decision
- GECC
- GLSI Strong Buy
- Analyst Count
- GECC 0
- GLSI 1
- Target Price
- GECC N/A
- GLSI $39.00
- AVG Volume (30 Days)
- GECC 22.1K
- GLSI 37.1K
- Earning Date
- GECC 05-05-2025
- GLSI 05-20-2025
- Dividend Yield
- GECC 14.00%
- GLSI N/A
- EPS Growth
- GECC N/A
- GLSI N/A
- EPS
- GECC 0.42
- GLSI N/A
- Revenue
- GECC $42,909,000.00
- GLSI N/A
- Revenue This Year
- GECC $33.52
- GLSI N/A
- Revenue Next Year
- GECC N/A
- GLSI N/A
- P/E Ratio
- GECC $25.19
- GLSI N/A
- Revenue Growth
- GECC 18.13
- GLSI N/A
- 52 Week Low
- GECC $8.87
- GLSI $8.06
- 52 Week High
- GECC $11.39
- GLSI $18.75
- Technical
- Relative Strength Index (RSI)
- GECC 54.55
- GLSI 46.54
- Support Level
- GECC $10.29
- GLSI $9.59
- Resistance Level
- GECC $10.70
- GLSI $10.10
- Average True Range (ATR)
- GECC 0.19
- GLSI 0.54
- MACD
- GECC -0.02
- GLSI 0.01
- Stochastic Oscillator
- GECC 69.88
- GLSI 27.61
About GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generate both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.